Genetic Technologies Stock Total Asset
| GTG Stock | 0.04 0.00 0.00% |
Genetic Technologies fundamentals help investors to digest information that contributes to Genetic Technologies' financial success or failures. It also enables traders to predict the movement of Genetic Stock. The fundamental analysis module provides a way to measure Genetic Technologies' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Genetic Technologies stock.
| Last Reported | Projected for Next Year | ||
| Total Assets | 6.2 M | 5.9 M |
Genetic | Total Asset |
Genetic Technologies Company Total Asset Analysis
Genetic Technologies' Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Genetic Technologies Total Asset | 6.19 M |
Most of Genetic Technologies' fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Genetic Technologies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
| Competition |
Genetic Total Assets
Total Assets |
|
Based on the latest financial disclosure, Genetic Technologies has a Total Asset of 6.19 M. This is much higher than that of the Life Sciences Tools & Services sector and significantly higher than that of the Health Care industry. The total asset for all Australia stocks is notably lower than that of the firm.
Genetic Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Genetic Technologies' direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Genetic Technologies could also be used in its relative valuation, which is a method of valuing Genetic Technologies by comparing valuation metrics of similar companies.Genetic Technologies is currently under evaluation in total asset category among its peers.
Genetic Fundamentals
| Return On Equity | -1.85 | ||||
| Return On Asset | -0.63 | ||||
| Profit Margin | (1.24) % | ||||
| Operating Margin | (1.13) % | ||||
| Current Valuation | 5.53 M | ||||
| Shares Outstanding | 145.42 M | ||||
| Shares Owned By Insiders | 5.56 % | ||||
| Price To Book | 3.10 X | ||||
| Price To Sales | 0.59 X | ||||
| Revenue | 7.66 M | ||||
| Gross Profit | 6.01 M | ||||
| EBITDA | (11.43 M) | ||||
| Net Income | (12.02 M) | ||||
| Total Debt | 875.19 K | ||||
| Book Value Per Share | 0.01 X | ||||
| Cash Flow From Operations | (9.68 M) | ||||
| Target Price | 0.25 | ||||
| Number Of Employees | 55 | ||||
| Beta | 0.48 | ||||
| Market Capitalization | 5.67 M | ||||
| Total Asset | 6.19 M | ||||
| Retained Earnings | (166.38 M) | ||||
| Working Capital | (500.09 K) | ||||
| Net Asset | 6.19 M |
About Genetic Technologies Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Genetic Technologies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Genetic Technologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Genetic Technologies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Genetic Stock Analysis
When running Genetic Technologies' price analysis, check to measure Genetic Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genetic Technologies is operating at the current time. Most of Genetic Technologies' value examination focuses on studying past and present price action to predict the probability of Genetic Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genetic Technologies' price. Additionally, you may evaluate how the addition of Genetic Technologies to your portfolios can decrease your overall portfolio volatility.